Our technology is based on a combination of bio-computation and fintech. Bio-computation covers precision medicine, which is the application of personalized therapy as well as other utilization in research and drug development. Our main output is information delivered via the cloud to provide a digital twin of the patient based on computer analysis of the comprehensive set of personal medical data, especially biomarkers. The Digital twin is a perfect companion for bio-computation which differs from bioinformatics by making use of patient-in-a-dish testing enabled by micro-physiological systems. Thus, our challenge is not only to collect, harmonize and analyze medical data, but to improve the quality of data which also includes the use of comprehensive genetic analysis as well as novel tools from 3rd parties like liquid biopsy and data from patient-in-a-dish testing that can greatly help to predict an individuals response to a specific treatment.

Additional innovation Sanus brings lies in finance and stems from creative sharing of revenue from medical data. We effectively de-fragment the pathology data, tapping into a vast usage that can lead to additional financial applications, including enabling true Digital Collateral (DiCo). In turn, DiCo empowers innovation in precision medicine closing the loop between Biotech which reinforces Fintech and vice versa. We call the combination of precision medicine and fintech innovation BioFinTech.